System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Review Research Support, Non-U.S. Gov't Ppublish 9 citations

PubMed: 39545748 DOI: 10.1111/1751-7915.70053

New insights for the development of efficient DNA vaccines.

Microb Biotechnol 17(11):e70053

Authors: Simone Berger, Yanira Zeyn, Ernst Wagner, Matthias Bros

Affiliations

  • Pharmaceutical Biotechnology, Department of Pharmacy, Center for NanoScience, Ludwig-Maximilians-Universität (LMU) Munich, Munich, Germany.
  • Department of Dermatology, University Medical Center of the Johannes Gutenberg University (JGU) Mainz, Mainz, Germany.

Abstract

Despite the great potential of DNA vaccines for a broad range of applications, ranging from prevention of infections, over treatment of autoimmune and allergic diseases to cancer immunotherapies, the implementation of such therapies for clinical treatment is far behind the expectations up to now. The main reason is the poor immunogenicity of DNA vaccines in humans. Consequently, the improvement of the performance of DNA vaccines in vivo is required. This mini-review provides an overview of the current state of DNA vaccines and the various strategies to enhance the immunogenic potential of DNA vaccines, including (i) the optimization of the DNA construct itself regarding size, nuclear transfer and transcriptional regulation; (ii) the use of appropriate adjuvants; and (iii) improved delivery, for example, by careful choice of the administration route, physical methods such as electroporation and nanomaterials that may allow cell type-specific targeting. Moreover, combining nanoformulated DNA vaccines with other immunotherapies and prime-boost strategies may help to enhance success of treatment.

MeSH

Vaccines, Immunotherapy, Biotechnology, Therapeutics, Dna, Vaccines, Dna

Cited by